Agno Pharma has acquired Actylis for an undisclosed amount, marking a significant corporate transaction. Actylis is a global solutions provider with over 75 years of experience, specializing in streamlining the management of critical ingredients and raw materials for its business partners. The company offers standard and custom ingredients through a rapidly growing portfolio of GMP and non-GMP facilities worldwide, complemented by a strong sourcing hub network.
This acquisition is strategically aimed at enhancing Agno Pharma's capabilities and expanding its footprint within the critical ingredients and raw materials sector. Actylis's unique hybrid model, blending manufacturing with global sourcing, along with its extensive experience in sourcing and distribution, is expected to significantly bolster Agno Pharma's supply chain resilience and global reach. The integration of Actylis's established infrastructure and expertise will allow Agno Pharma to offer a more comprehensive suite of services.
The combination of Agno Pharma and Actylis is anticipated to create substantial synergies, particularly in optimizing the procurement and delivery of essential materials. This move is set to improve operational efficiencies and broaden the combined entity's product and service offerings to customers reliant on high-quality, reliably managed ingredients.
The newly combined organization is poised to strengthen its position as a leading partner in the global supply chain for critical ingredients, providing enhanced value and a more robust, integrated solution for its diverse client base.